Literature DB >> 20596614

Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade.

Valeria Barresi1, Antonio Ieni, Davide Bolignano, Carlo Magno, Michele Buemi, Gaetano Barresi.   

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein with roles in iron trafficking as well as in carcinogenesis and progression of several human neoplasias. Although the renal proximal tubule represents a major source of NGAL synthesis under various injurious stimuli to the kidney, NGAL expression has been rarely evaluated in renal tumors up to now. In view of this, in the present study we analyzed the expression of this protein in renal tumors of different histotype and grade so as to evaluate whether a role for NGAL might be also proposed in the carcinogenesis of these neoplasms. NGAL immunoexpression was analyzed in 30 surgically resected renal tumors [18 clear cell, 5 papillary and 3 chromophobe renal cell carcinomas (RCCs), 2 urothelial carcinomas and 2 oncocytomas] and in the peritoneal metastasis of a clear cell RCC. A variable NGAL immunoexpression was found in 28/30 cases. High NGAL expression was significantly associated with the papillary and chromphobe histotypes (P=0.016) and with a higher histological grade of clear cell and papillary RCC (P=0.004). Moreover, NGAL expression was retained in the peritoneal metastasis of clear cell RCC. Our findings demonstrate that NGAL is expressed in several histotypes of renal tumors. Its highest expression in the papillary and chromophobe histotypes might be related to a higher need in iron uptake, which could be exploited in anti-cancer therapies with iron chelators against these neoplasias. Further studies are required to investigate the potential diagnostic utility of NGAL in the early diagnosis of metastatic progression of RCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596614     DOI: 10.3892/or_00000860

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland.

Authors:  Valeria Barresi; Enrica Vitarelli; Luca Reggiani Bonetti; Giovanni Tuccari; Gaetano Barresi
Journal:  Virchows Arch       Date:  2012-02-28       Impact factor: 4.064

2.  Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?

Authors:  Valeria Barresi; Roberta Lucianò; Enrica Vitarelli; Agata Labate; Giovanni Tuccari; Gaetano Barresi
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

3.  Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma.

Authors:  Amjad Shalabi; Zaid Abassi; Hoda Awad; Sarel Halachmi; Boaz Moskovitz; Yoram Kluger; Ofer Nativ
Journal:  World J Urol       Date:  2013-02-22       Impact factor: 4.226

Review 4.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

5.  ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).

Authors:  Hajer Ben Khadhra; Françoise Rose-Robert; Yves Edouard Herpe; Henri Sevestre; Gabriel Choukroun; Luc Catherine; Carole Amant; Fabien Saint
Journal:  Int Urol Nephrol       Date:  2020-08-12       Impact factor: 2.370

6.  Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.

Authors:  Antonia Sophie Wenners; Keyur Mehta; Sibylle Loibl; Hyerim Park; Berit Mueller; Norbert Arnold; Sigrid Hamann; Joerg Weimer; Beyhan Ataseven; Silvia Darb-Esfahani; Christian Schem; Christoph Mundhenke; Fariba Khandan; Christoph Thomssen; Walter Jonat; Hans-Juergen Holzhausen; Gunther von Minckwitz; Carsten Denkert; Maret Bauer
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

7.  Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression.

Authors:  P T Reilly; W L Teo; M J Low; A A Amoyo-Brion; C Dominguez-Brauer; A J Elia; T Berger; G Greicius; S Pettersson; T W Mak
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

8.  Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis.

Authors:  Julia K Meier; Matthias Schnetz; Susanne Beck; Tobias Schmid; Monica Dominguez; Sanela Kalinovic; Andreas Daiber; Bernhard Brüne; Michaela Jung
Journal:  Metabolites       Date:  2021-05-19

9.  Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors.

Authors:  Angelina DI Carlo
Journal:  Oncol Lett       Date:  2013-03-13       Impact factor: 2.967

10.  Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.

Authors:  Saverio Candido; Roberta Maestro; Jerry Polesel; Alessia Catania; Francesca Maira; Santo S Signorelli; James A McCubrey; Massimo Libra
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.